Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EGFRvIII CAR-T (Shenzhen BinDeBio)
- Development stage
- Unknown
- Lead developer
- Shenzhen Binde Biotechnology
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
EGFRvIII CAR-T (Shenzhen BinDeBio) is an autologous chimeric antigen receptor (CAR) T-cell therapy being developed by Shenzhen BinDeBio Ltd. (Shenzhen Binde Biotechnology Co., Ltd.) for the treatment of various solid tumors, including glioblastoma, hepatocellular carcinoma, esophageal cancer, and gastric cancer. The therapy involves genetically engineering a patient's own T lymphocytes to express a chimeric antigen receptor that specifically targets the Epidermal growth factor receptor variant III (EGFRvIII). EGFRvIII is a tumor-specific mutation frequently expressed in certain malignancies but absent in healthy tissues, making it a highly selective target for immunotherapy. Upon infusion, these modified T cells recognize and bind to EGFRvIII-positive tumor cells, leading to targeted cell lysis. The therapy is currently being evaluated in Phase I/II clinical trials as part of a multi-target immunotherapy platform.
- Other names
- EGFRvIII-targeting CAR-T cellsanti-EGFRvIII CAR-TShenzhen BinDeBio EGFRvIII CAR-T
02
Targets
EGFRvIII (Epidermal growth factor receptor variant III)
Beyond the preview
Go deeper on EGFRvIII CAR-T (Shenzhen BinDeBio).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EGFRvIII CAR-T (Shenzhen BinDeBio).